← Leaderboards
Hector Hugo Garcia
Universidad Peruana Cayetano Heredia
$15,933,000
Attributed
$20,031,996
Total exposure
15
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.1M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$26,234,059 · 18
By mechanism
D43$6,201,381 · 2
U01$5,838,427 · 4
R01$5,675,018 · 2
U19$3,774,425 · 3
P01$3,328,127 · 2
R21$654,283 · 2
Top collaborators
- Seth E O'Neal7 shared
- Joseph Raymond Zunt6 shared
- Robert H Gilman5 shared
- Sarah Odell Gimbel5 shared
- David L Tirschwell4 shared
- Miguel Mauricio Cabada3 shared
Most similar at Universidad Peruana Cayetano Heredia
Same institution · by research overlap
- Miguel Mauricio Cabada$4,387,032
- Saul J Santivanez$675,000
- Javier A Bustos$2,011,690
- Joseph Raymond Zunt$11,635,157
- Patricia Jannet Garcia$2,913,688
Others in their field
Top investigators on “Peru”
- Lawrence Corey · Fred Hutchinson Cancer Center$205,096,160
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$45,710,868
- Fred M Gordin · Social And Scientific Systems, Inc.$44,160,542
- Clarence Buddy Creech · Vanderbilt University Medical Center$43,087,946
- Robert M. Grant · J. David Gladstone Institutes$41,279,316
Research focus
PeruProgramsResearch PersonnelFundingGrantNeurocysticercosisParasitesAntiparasitic AgentsTrainingTaenia SoliumClinical ResearchEpilepsyBrainBaseDeveloping CountriesMorbidity - Disease RateStudentsPrincipal InvestigatorAreaAntigensSafetySeizuresClinical TrialsSampling
Grant awards (87)
A multicenter, randomized controlled trial of single and multiple dose regimes of oxfendazole for mild (one or two lesions) parenchymal brain cysticercosis$941,896
U01 · FY2025 · AI · contact PI
A Non-Inferiority Randomized Single Blind Controlled Trial Comparing One and Two Dose Regimes of Oxfendazole versus a Two Dose Regime of Triclabendazole to Treat Chronic Fascioliasis$561,459
U01 · FY2025 · AI · contact PI
Training in Infectious Diseases in Peru - Time for Implementation Research$290,320
D43 · FY2025 · TW · contact PI
A multicenter, randomized controlled trial of single and multiple dose regimes of oxfendazole for mild (one or two lesions) parenchymal brain cysticercosis$944,056
U01 · FY2024 · AI · contact PI
A Non-Inferiority Randomized Single Blind Controlled Trial Comparing One and Two Dose Regimes of Oxfendazole versus a Two Dose Regime of Triclabendazole to Treat Chronic Fascioliasis$549,802
U01 · FY2024 · AI · contact PI
Training in Infectious Diseases in Peru - Time for Implementation Research$289,680
D43 · FY2024 · TW · contact PI
Urine Screening for Early Detection of Subarachnoid Neurocysticercosis$562,169
R01 · FY2023 · NS
A multicenter, randomized controlled trial of single and multiple dose regimes of oxfendazole for mild (one or two lesions) parenchymal brain cysticercosis$514,732
U01 · FY2023 · AI · contact PI
A Non-Inferiority Randomized Single Blind Controlled Trial Comparing One and Two Dose Regimes of Oxfendazole versus a Two Dose Regime of Triclabendazole to Treat Chronic Fascioliasis$439,115
U01 · FY2023 · AI · contact PI
Training in Infectious Diseases in Peru - Time for Implementation Research$290,321
D43 · FY2023 · TW · contact PI
Interdisciplinary Cerebrovascular Diseases Training Program in South America$261,615
D43 · FY2023 · TW
Urine screening for early detection of subarachnoid neurocysticercosis$593,759
R01 · FY2022 · NS
Training in Infectious Diseases in Peru - Time for Implementation Research$290,320
D43 · FY2022 · TW · contact PI
Interdisciplinary Cerebrovascular Diseases Training Program in South America$262,520
D43 · FY2022 · TW
Improving Diagnostic and Management Tools for Neurocysticercosis (Peru-JHU TMRC Program)$547,763
U19 · FY2021 · AI · contact PI
Training in Infectious Diseases in Peru - Time for Implementation Research$294,960
D43 · FY2021 · TW · contact PI
Administrative Core$131,630
U19 · FY2021 · AI · contact PI
Biomarkers for Monitoring Treatment Efficacy in Human Neurocysticercosis$48,924
U19 · FY2021 · AI · contact PI
Urine screening for early detection of subarachnoid neurocysticercosis$31,570
R01 · FY2021 · NS
Urine screening for early detection of subarachnoid neurocysticercosis$587,654
R01 · FY2020 · NS
Improving Diagnostic and Management Tools for Neurocysticercosis (Peru-JHU TMRC Program)$536,121
U19 · FY2020 · AI · contact PI
Training in Infectious Diseases in Peru â Time for Capacity Strengthening in Clinical Research$269,520
D43 · FY2020 · TW · contact PI
Interdisciplinary Cerebrovascular Diseases Training Program in South America$263,030
D43 · FY2020 · TW
Administrative Core$229,684
U19 · FY2020 · AI · contact PI
Population Assessment of Alzheimer's and Related Dementias in Rural Northern Peru$149,111
R21 · FY2020 · AG
Biomarkers for Monitoring Treatment Efficacy in Human Neurocysticercosis$48,924
U19 · FY2020 · AI · contact PI
Urine screening for early detection of subarachnoid neurocysticercosis$31,570
R01 · FY2020 · NS
Urine screening for early detection of subarachnoid neurocysticercosis$588,579
R01 · FY2019 · NS
Improving Diagnostic and Management Tools for Neurocysticercosis (Peru-JHU TMRC Program)$541,086
U19 · FY2019 · AI · contact PI
Training in Infectious Diseases in Peru â Time for Capacity Strengthening in Clinical Research$269,520
D43 · FY2019 · TW · contact PI
Interdisciplinary Cerebrovascular Diseases Training Program in South America$264,059
D43 · FY2019 · TW
Population Assessment of Alzheimer's and Related Dementias in Rural Northern Peru$162,986
R21 · FY2019 · AG
Administrative Core$160,110
U19 · FY2019 · AI · contact PI
Combined Albendazole and Praziquantel in Subarachnoid NCC, CCC, Lead application$105,160
U01 · FY2019 · NS · contact PI
Biomarkers for Monitoring Treatment Efficacy in Human Neurocysticercosis$46,332
U19 · FY2019 · AI · contact PI
Urine screening for early detection of subarachnoid neurocysticercosis$597,785
R01 · FY2018 · NS
Improving Diagnostic and Management Tools for Neurocysticercosis (Peru-JHU TMRC Program)$565,811
U19 · FY2018 · AI · contact PI
Combined Albendazole and Praziquantel in Subarachnoid NCC, CCC, Lead application$422,890
U01 · FY2018 · NS · contact PI
Training in Infectious Diseases in Peru â Time for Capacity Strengthening in Clinical Research$269,520
D43 · FY2018 · TW · contact PI
Administrative Core$126,489
U19 · FY2018 · AI · contact PI
Biomarkers for Monitoring Treatment Efficacy in Human Neurocysticercosis$51,524
U19 · FY2018 · AI · contact PI
Improving Diagnostic and Management Tools for Neurocysticercosis (Peru-JHU TMRC Program)$565,715
U19 · FY2017 · AI · contact PI
Combined Albendazole and Praziquantel in Subarachnoid NCC, CCC, Lead application$421,948
U01 · FY2017 · NS · contact PI
Training in Infectious Diseases in Peru â Time for Capacity Strengthening in Clinical Research$269,520
D43 · FY2017 · TW · contact PI
Characterization of hippocampal sclerosis in individuals with calcified Neurocysticercosis$124,662
R21 · FY2017 · NS · contact PI
Administrative Core$122,796
U19 · FY2017 · AI · contact PI
Biomarkers for Monitoring Treatment Efficacy in Human Neurocysticercosis$51,516
U19 · FY2017 · AI · contact PI
Combined Albendazole and Praziquantel in Subarachnoid NCC, CCC, Lead application$422,748
U01 · FY2016 · NS · contact PI
Training in Infectious Diseases in Peru â Time for Capacity Strengthening in Clinical Research$272,000
D43 · FY2016 · TW · contact PI
Characterization of hippocampal sclerosis in individuals with calcified Neurocysticercosis$217,524
R21 · FY2016 · NS · contact PI
Combined Albendazole and Praziquantel in Subarachnoid NCC, CCC, Lead application$426,546
U01 · FY2015 · NS · contact PI
Training in Infectious Diseases in Peru$242,447
D43 · FY2015 · TW · contact PI
Training in Infectious Diseases in Peru$242,472
D43 · FY2014 · TW · contact PI
Training in Infectious Diseases in Peru$237,456
D43 · FY2013 · TW · contact PI
Training in Infectious Diseases in Peru$249,989
D43 · FY2012 · TW · contact PI
Neurocysticercosis: Combined Treatment with Praziquantel and Albendazole$206,000
R01 · FY2012 · NS · contact PI
Neurocysticercosis: Combined Treatment with Praziquantel and Albendazole$54,000
R01 · FY2012 · NS · contact PI
Training in Infectious Diseases in Peru$249,989
D43 · FY2011 · TW · contact PI
Administrative Core$122,779
P50 · FY2011 · AI · contact PI
Neurocysticercosis: Combined Treatment with Praziquantel and Albendazole$385,318
R01 · FY2010 · NS · contact PI
Training in Infectious Diseases in Peru$181,306
D43 · FY2010 · TW · contact PI
Administrative Core$122,368
P50 · FY2010 · AI · contact PI
Neurocysticercosis: Combined Treatment with Praziquantel and Albendazole$444,490
R01 · FY2009 · NS · contact PI
Training in Infectious Diseases in Peru$199,976
D43 · FY2009 · TW · contact PI
Training in Infectious Diseases in Peru$181,402
D43 · FY2009 · TW · contact PI
Administrative Core$121,466
P50 · FY2009 · AI · contact PI
Neurocysticercosis: Combined Treatment with Praziquantel and Albendazole$525,879
R01 · FY2008 · NS · contact PI
Training in Infectious Diseases in Peru$150,000
D43 · FY2008 · TW · contact PI
Training in Infectious Diseases in Peru$141,717
D43 · FY2008 · TW · contact PI
Administrative Core$119,292
P50 · FY2008 · AI · contact PI
Neurocysticercosis: Combined Treatment with Praziquantel and Albendazole$47,952
R01 · FY2008 · NS · contact PI
Neurocysticercosis: Combined Treatment with Praziquantel and Albendazole$518,690
R01 · FY2007 · NS · contact PI
Administrative Core$159,053
P50 · FY2007 · AI · contact PI
Training in Parasitic Diseases and Central Nervous System Infections in Peru.$131,914
D43 · FY2007 · TW · contact PI
New Tools to Understand and Control Endemic Parasites$701,667
P01 · FY2006 · AI · contact PI
Neurocysticercosis: Combined Treatment with Praziquantel and Albendazole$499,603
R01 · FY2006 · NS · contact PI
Training in Infectious Diseases in Peru$135,808
D43 · FY2006 · TW · contact PI
New Tools to Understand and Control Endemic Parasites$702,790
P01 · FY2005 · AI
New Tools to Understand and Control Endemic Parasites$681,995
P01 · FY2004 · AI
New Tools to Understand and Control Endemic Parasites$667,596
P01 · FY2003 · AI
New Tools to Understand and Control Endemic Parasites$574,079
P01 · FY2002 · AI
Understanding human cysticerosis: Natural evolution of infection and disease$0
U01 · FY2002 · AI
Pre-symptomatic Neurocysticercosis:Synthetic Antigens for Detection &Prevention$0
P01 · FY2002 · AI
New Tools to Understand and Control Endemic Parasites$117,440
P20 · FY2001 · AI
Understanding human cysticerosis: Natural evolution of infection and disease$0
U01 · FY2001 · AI
Unveiling the Dynamics of Taenia solium Cysticercosis$0
P20 · FY2001 · AI
Understanding human cysticerosis: Natural evolution of infection and disease$88,075
U01 · FY2000 · AI